Business Context and Reporting Period
Ionis Pharmaceuticals, Inc. is an RNA-targeted therapeutics company operating as a single segment, including wholly owned subsidiary Akcea Therapeutics. This unaudited Form 10-Q covers the three months ended March 31, 2024, with comparison to the three months ended March 31, 2023.
Ionis had five marketed medicines: SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. WAINUA launched in the United States in January 2024. The company reported nine medicines in registration or Phase 3 development across eleven indications.
Financial Results and Key Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $119.5 million | $130.5 million | Down 8.5% |
| Commercial revenue | $59.6 million | $67.8 million | Down 12.1% |
| Research and development revenue | $59.9 million | $62.8 million | Down 4.5% |
| Total operating expenses | $269.0 million | $244.7 million | Up 9.9% |
| Loss from operations | $(149.5) million | $(114.1) million | Loss increased |
| Net loss | $(142.8) million | $(124.3) million | Loss increased |
| Net loss per share | $(0.98) | $(0.87) | Loss per share increased |
| Operating cash flow | $(149.9) million | $(134.0) million | Cash use increased |
Approximate operating margin was negative 125% in Q1 2024 versus negative 87% in Q1 2023. Approximate net margin was negative 120% versus negative 95%. Operating expenses excluding non-cash equity compensation increased to $237.7 million from $217.7 million; stock-based compensation increased to $31.3 million from $26.9 million.
- SPINRAZA royalties declined to $38.5 million from $50.2 million, primarily due to shipment timing outside the United States, while management said global patient numbers remained consistent.
- WAINUA generated $1.1 million of royalties following its U.S. launch and $10.6 million of joint-development revenue, down from $24.4 million as ATTRv-PN development activities wound down.
- Collaborative agreement revenue increased to $49.3 million from $38.4 million, primarily due to amortization of upfront payments from collaborations entered into during 2023 with Roche and Novartis.
- Investment income increased to $26.3 million from $18.6 million, primarily because of higher interest rates. Interest expense increased to $4.2 million from $1.6 million.
- Interest expense related to the sale of future royalties was $18.0 million, compared with $15.5 million in the prior-year period.
Liquidity, Debt and Balance Sheet
| Balance-sheet item | March 31, 2024 | December 31, 2023 |
|---|---|---|
| Cash and cash equivalents | $348.9 million | $399.3 million |
| Short-term investments | $1.857 billion | $1.932 billion |
| Cash, cash equivalents and short-term investments | $2.206 billion | $2.331 billion |
| Total assets | $2.764 billion | $2.990 billion |
| Total liabilities | $2.467 billion | $2.603 billion |
| Stockholders’ equity | $296.5 million | $386.7 million |
Net cash decreased by $50.4 million during the quarter. Investing activities provided $76.1 million, primarily because proceeds from short-term investment sales exceeded purchases. Financing activities provided $23.6 million, primarily from employee equity plans. Capital expenditures were $4.5 million.
Convertible debt principal totaled approximately $1.252 billion: $575.0 million of 1.75% notes due June 2028, $632.5 million of 0% notes due April 2026, and $44.5 million of 0.125% notes due December 2024. The royalty-sale liability was $525.1 million at March 31, 2024, with an estimated effective interest rate of 13.5%. Total contractual obligations, excluding the royalty-sale liability, were $1.583 billion, including $44.6 million due within one year.
Management stated that cash, cash equivalents, short-term investments and expected future cash plans should be sufficient to fund planned operations and contractual obligations. The company also noted that it may pursue equity, debt, refinancing, credit facilities or additional royalty monetizations depending on business and market conditions.
Material Changes, Outlook and Unusual Items
- WAINUA commercialization began in the United States in January 2024. AstraZeneca funds 55% of costs associated with the ongoing global Phase 3 development program and is responsible for most U.S. commercial and medical-affairs costs and all costs associated with commercialization outside the United States.
- SG&A increased primarily because of WAINUA commercialization and launch preparation for olezarsen and donidalorsen. R&D increased because of the timing of late-stage programs.
- Management expects R&D expenses to stabilize as several late-stage studies end and resources are reallocated to earlier-stage programs. However, operating expenses excluding equity compensation are expected to continue increasing during the remainder of 2024 as commercialization activities advance.
- The filing does not provide formal full-year revenue, earnings or cash-flow guidance.
- Olezarsen’s NDA for familial chylomicronemia syndrome was pending FDA acceptance at the filing date; donidalorsen was being prepared for FDA submission. WAINUA ATTR-CM data were expected as early as 2025.
- The company recognized $2.3 million of net investment gains versus a $0.5 million loss in the prior-year period. It also recorded $75 thousand of income tax expense versus $11.4 million, primarily because the 2023 royalty transaction created taxable income in the prior-year period. Ionis continues to maintain a full valuation allowance on its net deferred tax assets.
- Revenue remains concentrated among collaboration partners: Biogen represented 50% of Q1 2024 revenue and AstraZeneca represented 10%. Biogen-related deferred contract revenue was $287.2 million at March 31, 2024.
- The company reported no pending material legal proceedings, no substantive changes to its previously disclosed risk factors, and effective disclosure controls as of March 31, 2024.
Principal Risks and Contingencies
- Continued operating losses, negative operating cash flow and the need for substantial investment in clinical development and commercialization.
- Dependence on Biogen, AstraZeneca and other partners for development, regulatory approval, manufacturing and commercialization; partners may reduce funding or terminate collaborations.
- Clinical, regulatory and manufacturing risks, including failure of trials, delayed approvals, post-approval obligations and product-safety issues.
- Competition and reimbursement, pricing and market-access pressure affecting SPINRAZA, WAINUA, TEGSEDI, WAYLIVRA and pipeline medicines.
- SPINRAZA royalty declines or lower-than-expected pelacarsen development or sales could reduce royalties available to Ionis and affect the royalty-sale liability estimate.
- Potential dilution or cash requirements associated with convertible notes, warrants and future financing.
- Cybersecurity, intellectual-property, supply-chain, geopolitical, foreign-exchange and natural-disaster risks.
Investor Verification Checklist
- Verify the sustainability of WAINUA adoption, royalty revenue and the economics of the U.S. launch.
- Monitor SPINRAZA sales and shipment timing, QALSODY royalties and the effect of competitive therapies.
- Track FDA acceptance and review of the olezarsen NDA, regulatory submissions for donidalorsen, and WAINUA ATTR-CM development milestones.
- Reconcile cash burn with the $2.206 billion of cash, cash equivalents and short-term investments and the company’s planned commercialization spending.
- Assess refinancing or settlement requirements for the $632.5 million of 0% notes due April 2026 and the $44.5 million of 0.125% notes due December 2024.
- Review the assumptions underlying the 13.5% effective interest rate and future royalty-payment estimates under the Royalty Pharma agreement.
- Evaluate revenue concentration, particularly the 50% contribution from Biogen and the company’s dependence on collaboration funding.